- Home
- COEP vs CRDL Comparison
COEP vs CRDL Comparison
Compare COEP & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COEP
- CRDL
- Stock Information
- Founded
- COEP 2017
- CRDL 2017
- Country
- COEP United States
- CRDL Canada
- Employees
- COEP N/A
- CRDL N/A
- Industry
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- COEP Health Care
- CRDL Health Care
- Exchange
- COEP Nasdaq
- CRDL Nasdaq
- Market Cap
- COEP 86.0M
- CRDL 90.4M
- IPO Year
- COEP N/A
- CRDL N/A
- Fundamental
- Price
- COEP $16.95
- CRDL $1.07
- Analyst Decision
- COEP
- CRDL Strong Buy
- Analyst Count
- COEP 0
- CRDL 2
- Target Price
- COEP N/A
- CRDL $9.00
- AVG Volume (30 Days)
- COEP 63.6K
- CRDL 781.9K
- Earning Date
- COEP 11-12-2025
- CRDL 11-13-2025
- Dividend Yield
- COEP N/A
- CRDL N/A
- EPS Growth
- COEP N/A
- CRDL N/A
- EPS
- COEP N/A
- CRDL N/A
- Revenue
- COEP $263,555.00
- CRDL N/A
- Revenue This Year
- COEP N/A
- CRDL N/A
- Revenue Next Year
- COEP N/A
- CRDL N/A
- P/E Ratio
- COEP N/A
- CRDL N/A
- Revenue Growth
- COEP N/A
- CRDL N/A
- 52 Week Low
- COEP $2.31
- CRDL $0.77
- 52 Week High
- COEP $19.19
- CRDL $2.24
- Technical
- Relative Strength Index (RSI)
- COEP 59.29
- CRDL 44.73
- Support Level
- COEP $16.00
- CRDL $1.04
- Resistance Level
- COEP $18.15
- CRDL $1.16
- Average True Range (ATR)
- COEP 1.60
- CRDL 0.06
- MACD
- COEP 0.06
- CRDL 0.00
- Stochastic Oscillator
- COEP 63.31
- CRDL 20.83
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.